The breast journal
-
Comparative Study
Treatment variation by insurance status for breast cancer patients.
Few studies have examined the relationship of insurance status with the presentation and treatment of breast cancer. Using a state cancer registry, we compared tumor presentation and surgical treatments at presentation by insurance status (private insurance, Medicare, Medicaid, or uninsured). Student's t-test, Chi-square test, and ANOVA were used for comparison. ⋯ The presentation of breast cancer in women with no insurance and Medicaid is significantly worse than those with private insurance. Of concern are the lower proportions of BCS and reconstruction among patients who are uninsured or have Medicaid. Reduction of disparities in breast cancer presentation and treatment may be possible by increasing enrollment of uninsured, program-eligible women in a state-supported screening and treatment program.
-
The role of sentinel lymph node (SLN) biopsy in patients with initial diagnosis of ductal carcinoma in situ (DCIS) is still a dilemma. Different studies are trying to define predicting factors of invasive cancer in DCIS. The aim of this study was to confirm the value of SLN biopsy in DCIS because of the invasive upstaging risk on final histology. ⋯ SLN micrometastases and isolated cells were detected by IHC and secondary complete ALND found an additional metastatic lymph node in one patient. Tumor size larger than 30 mm and mastectomy were the only significative predicting factors of upstaged disease (p < 0.0001) in our study. In patients with initial diagnosis of large DCIS programmed for mastectomy, SLN biopsy should be discussed in order to detect underlying invasive disease and to spare patients a second operating time.
-
Randomized Controlled Trial Controlled Clinical Trial
Reduction of postoperative nausea and vomiting and analgesic requirement with dexamethasone in women undergoing general anesthesia for mastectomy.
Dexamethasone has antiemetic and analgesic effects in various types of surgery. In a randomized, double-blind, placebo-controlled trial, we evaluated the efficacy of dexamethasone for reducing postoperative nausea and vomiting (PONV) and analgesic requirement in women undergoing general anesthesia for mastectomy. Patient were allocated randomly to one of three groups (n=30 of each) to receive intravenously either placebo or dexamethasone at two different doses (4 mg, 8 mg) at the end of surgery. ⋯ No difference in analgesic requirement was found between the dexamethasone 4 mg and placebo groups (p=0.18). No clinically serious adverse events attributed to the study drug were observed in any of the groups. We conclude that dexamethasone 8 mg effectively decreases PONV and analgesic requirement in women undergoing general anesthesia for mastectomy.
-
Calciphylaxis is a rare disorder characterized by microcalcification of small- and medium-sized blood vessels causing cutaneous and soft tissue necrosis. Patients usually present with painful, violaceous skin discoloration in a livedo reticularis pattern. We present a case of a 59-year-old woman with end-stage renal disease (ESRD) who manifested signs and symptoms of inflammatory breast cancer. ⋯ We propose that those patients with ESRD who develop breast pathology consistent with inflammation and necrosis, and have no malignancy, be evaluated for secondary hyperparathyroidism. Total parathyroidectomy with reimplantation should be performed. Mastectomy should be performed for unresolving symptoms, necrosis or infection.
-
To investigate the effectiveness of adjuvant tamoxifen in older women with early-stage breast cancer. Between 1997 and 1999, women > or = 65 years old at diagnosis with stage I-IIIa breast cancer were recruited from four geographic regions of the United States and followed prospectively for 5 years after diagnosis. Data sources included tumor registries, medical records review, and telephone interviews. ⋯ The ratio of adjusted breast cancer mortality hazards was 0.61 (95% CI = 0.31-1.12) for the ever tamoxifen group versus the never tamoxifen group. Similarly, the 5-year overall survival was 81% (95% CI = 76-85) and 70% (95% CI = 61-78) for the ever tamoxifen and never tamoxifen groups, respectively, with an adjusted hazard ratio of 0.53 (95% CI = 0.37-0.77). Adjuvant tamoxifen is associated with improvement in 5-year breast cancer-specific and overall survival in older women with early-stage breast cancer.